144 related articles for article (PubMed ID: 38353881)
1. Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study.
Franchi C; Rossio R; Mandelli S; Ardoino I; Nobili A; Peyvandi F; Mannucci PM;
Intern Emerg Med; 2024 Apr; 19(3):689-696. PubMed ID: 38353881
[TBL] [Abstract][Full Text] [Related]
2. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes.
Mortensen EM; Nakashima B; Cornell J; Copeland LA; Pugh MJ; Anzueto A; Good C; Restrepo MI; Downs JR; Frei CR; Fine MJ
Clin Infect Dis; 2012 Dec; 55(11):1466-73. PubMed ID: 22918991
[TBL] [Abstract][Full Text] [Related]
3. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
Lee HY; Cooke CE; Robertson TA
J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
[TBL] [Abstract][Full Text] [Related]
4. Patients with Prior Exposure to a Combination of Statins & Angiotensin-Converting Enzyme Inhibitors (ACE-Is)/Angiotensin Receptor Blockers (ARBs) Have Better Outcomes after Carotid Revascularization than Patients with Prior Exposure to Statins Alone: A MultiCenter Analysis.
Willie-Permor D; Rahgozar S; Zarrintan S; Alsaigh T; Gaffey AC; Malas MB
Ann Vasc Surg; 2024 Mar; 100():165-171. PubMed ID: 37852362
[TBL] [Abstract][Full Text] [Related]
5. Do outpatient statins and ACEIs/ARBs have synergistic effects in reducing the risk of pneumonia? A population-based case-control study.
Kang JH; Kao LT; Lin HC; Wang TJ; Yang TY
PLoS One; 2018; 13(6):e0199981. PubMed ID: 29953536
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
7. The association of cardioprotective medications with pneumonia-related outcomes.
Wu A; Good C; Downs JR; Fine MJ; Pugh MJ; Anzueto A; Mortensen EM
PLoS One; 2014; 9(1):e85797. PubMed ID: 24489672
[TBL] [Abstract][Full Text] [Related]
8. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
Korhonen MJ; Robinson JG; Annis IE; Hickson RP; Bell JS; Hartikainen J; Fang G
J Am Coll Cardiol; 2017 Sep; 70(13):1543-1554. PubMed ID: 28935030
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
Li EC; Heran BS; Wright JM
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386
[TBL] [Abstract][Full Text] [Related]
10. Impact of diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis.
Ma J; Khalidi N; Wierzbicki O; Alqutami A; Ioannidis G; Pagnoux C
Int J Rheum Dis; 2020 Aug; 23(9):1233-1239. PubMed ID: 32776676
[TBL] [Abstract][Full Text] [Related]
11. Pneumonia risk and use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.
Liu CL; Shau WY; Chang CH; Wu CS; Lai MS
J Epidemiol; 2013 Sep; 23(5):344-50. PubMed ID: 23912052
[TBL] [Abstract][Full Text] [Related]
12. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins.
Chae YK; Valsecchi ME; Kim J; Bianchi AL; Khemasuwan D; Desai A; Tester W
Cancer Invest; 2011 Nov; 29(9):585-93. PubMed ID: 21936625
[TBL] [Abstract][Full Text] [Related]
13. The effect of angiotensin-converting enzyme inhibitors and statins on the progression of aortic sclerosis and mortality.
Ardehali R; Leeper NJ; Wilson AM; Heidenreich PA
J Heart Valve Dis; 2012 May; 21(3):337-43. PubMed ID: 22808835
[TBL] [Abstract][Full Text] [Related]
14. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19.
Khera R; Clark C; Lu Y; Guo Y; Ren S; Truax B; Spatz ES; Murugiah K; Lin Z; Omer SB; Vojta D; Krumholz HM
J Am Heart Assoc; 2021 Jul; 10(13):e018086. PubMed ID: 33624516
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use.
Shin J; Kim H; Yim HW; Kim JH; Lee S; Kim HS
J Clin Pharm Ther; 2022 Jan; 47(1):97-103. PubMed ID: 34668200
[TBL] [Abstract][Full Text] [Related]
16. Renin-Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study.
Christiansen CF; Heide-Jørgensen U; Rasmussen TB; Bodilsen J; Søgaard OS; Maeng M; Vistisen ST; Schmidt M; Pottegård A; Lund LC; Reilev M; Hallas J; Johansen NB; Brun NC; Sørensen HT; Thomsen RW
J Am Heart Assoc; 2020 Oct; 9(19):e017297. PubMed ID: 32998607
[TBL] [Abstract][Full Text] [Related]
17. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.
Lee HY; Ahn J; Park J; Kang CK; Won SH; Kim DW; Park JH; Chung KH; Joh JS; Bang JH; Kang CH; Oh MD; Pyun WB; ;
Korean J Intern Med; 2021 May; 36(3):617-628. PubMed ID: 33858123
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
[TBL] [Abstract][Full Text] [Related]
19. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
20. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
